Skip to main content
. 2020 Apr 29;6(18):eaax1346. doi: 10.1126/sciadv.aax1346

Fig. 6. Therapeutic efficacy of the nanoformulation in vivo.

Fig. 6

(A) Photographs of 4T1 and A375 tumor–bearing mice through the 21-day treatment period, PBS (I), ACC-CaSi-PAMAM-FA/mPEG (II), DOX (III), ACC@DOX-CaSi-PAMAM-FA/mPEG (IV) and ACC@DOX.Fe2+-CaSi-PAMAM-FA/mPEG (V). (B) Comparison of tumor tissues extracted from 4T1 and A375 tumor–bearing mice after the 21-day treatment period, PBS (I), ACC-CaSi-PAMAM-FA/mPEG (II), DOX (III), ACC@DOX-CaSi-PAMAM-FA/mPEG (IV) and ACC@DOX.Fe2+-CaSi-PAMAM-FA/mPEG (V). (C) Changes in the tumor volumes of the 4T1 tumor–bearing mice (six mice in each group) plotted against time, the tumor volume was measured every 2 days. (D) Final weight of tumor tissues extracted from 4T1 and A375 tumor–bearing mice after the 21-day treatment period. PBS (I), ACC-CaSi-PAMAM-FA/mPEG (II), DOX (III), ACC@DOX-CaSi-PAMAM-FA/mPEG (IV) and ACC@DOX.Fe2+-CaSi-PAMAM-FA/mPEG (V). (E) Survival rate of 4T1 tumor–bearing mice in 60 days (six mice in each group). (F) Survival rate of A375 tumor–bearing mice in 60 days (six mice in each group). Photo credit: Chen-Cheng Xue, Chongqing University.